We plan to run occasional articles on this website about aspects of WM research and treatment, specific to Canada and Canadian patients. If you have any suggestions for topics that you would like to see explored or commented on, you can email your suggestions or questions to wm.in.Canada@wmfc.ca.
Although these are neither medical advice nor the opinion of the WMFC Board, we hope that as educational material, these help you navigate the Canadian world of WM.
Current Canadian Research in WM
The WMFC and IWMF are co-funding cutting edge WM research at the Odette Cancer Centre, Sunnybrook Hospital, in Toronto.
Two major WM events are occurring at Sunnybrook. The first is Dr. Neil Berinstein’s pan-Canadian BRAWM trial that is headquartered at Sunnybrook. This exciting trial combines Bendamustine, Rituximab and the BTK inhibitor, Acalabrutinib (BRA) for first line treatment in WM. Within a few months it is expected that the trial will have filled all 59 openings in this coast-to-coast trial.
The second event arises from the first. Patients in the BRAWM trial have blood and marrow samples taken before, during and after the […]
WMFC and LLSC Announce a WM-focussed Operating Grant
The WMFC, in partnership with the Leukemia and Lymphoma Society of Canada (LLSC), is pleased to announce the availability of an Operating Grant for research into WM.
An Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer — in our case, specifically for WM.
All the details are available at the LLSC website on Operating Grants, but the highlights of such an award are as follows:
- Available to researchers at Canadian institutions
- Funding is for up […]
WM and DVT — One Member’s Cautionary Story
Ed. note: Many of us need to go the Emergency department from time to time, for things not related to WM. During the discussion of our symptoms with the triage nurse, there is the inevitable request along the lines of, “Tell me about your medical history”. Of course, we obediently mention that we have “Waldenstrom’s Macroglobulinemia”. They express puzzlement. We spell it for them; they type it into our medical record. Possibly correctly. We explain that it is an indolent form of non-Hodgkin Lymphoma. That they understand.
But not all non-Hodgkin Lymphomas have the […]
How many of us are there, anyway?
How many WMers are there in Canada? And how do we know?
The “urban myth” says “oh, there are about 150 people diagnosed with WM in Canada every year”. But for some of us, this wasn’t enough. We wanted to know. And it just wasn’t enough to refer to the urban myth.
The obvious place to look is, perhaps, the Canadian Cancer Society (the CCS). They publish an annual report containing extensive statistics on cancer in Canada. The latest one, for 2021, is an excellent reference. Unfortunately, while the CCS does a great job breaking down the […]
Another Clinical Trial Available in Canada: Nemtabrutinib
Nemtabrutinib (a.k.a. MK-1026 and ARQ 531) is a BTK inhibitor, but, similar to Pirtobrutinib (LOXO-305), has a reversible (“non-covalent”) binding behaviour to the BTK site. (For more information on its chemistry, see this site.)
An open-label phase 2 trial of Nemtabrutinib, including WM patients, is now recruiting at locations around the world. In particular, three (as of May 24/2022) Canadian locations are included:
- The Tom Baker Cancer Centre, Calgary, AB; Study co-ordinator is at (403) 521-3723
- The Jewish General Hospital, Montreal, QC; Study co-ordinator is at (514) 340-8222, x24572
- The Ottawa Hospital, Ottawa, ON; Study co-ordinator […]
